Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib plus CDK4/6 inhibitor and letrozole versus placebo plus CDK4/6 inhibitor and letrozole in PIK3CA-mutated HR-positive HER2-negative advanced breast cancer
2024-516162-11-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of inavolisib in breast cancer (4 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Planned start Jul 2025; status: authorised.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516162-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516162-11-00.